Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib

por Chuah, Charles, Melo, Junia V
Publicado 2009

Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress

por Xiang, Wei, Lam, Yi Hui, Periyasamy, Giridharan, Chuah, Charles
Publicado 2022

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

por Rauzan, Muhammad, Chuah, Charles T. H., Ko, Tun Kiat, Ong, S. Tiong
Publicado 2017

High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresis

por Ramlee, Muhammad Khairul, Yan, Tingdong, Cheung, Alice M. S., Chuah, Charles T. H., Li, Shang
Publicado 2015

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

por Chuah, Charles T., Nakamae, Hirohisa, Shen, Zhixiang X., Bradley-Garelik, M. Brigid, Kim, Dong-Wook
Publicado 2014

Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia()

por Lam Yi, Hui, Than, Hein, Sng, Colin, Cheong, May Anne, Chuah, Charles, Xiang, Wei
Publicado 2019

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

por Ko, Tun Kiat, Chuah, Charles T.H., Huang, John W.J., Ng, King-Pan, Ong, S. Tiong
Publicado 2014

Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia

por Lee, Kian Leong, Ko, Tun Kiat, Saw, Nicole Y. L., Javed, Asif, Hillmer, Axel M., Chuah, Charles, Krishnan, Vaidehi, Ong, S. Tiong
Publicado 2022

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia

por Ko, Tun Kiat, Chin, Hui San, Chuah, Charles T.H., Huang, John W.J., Ng, King-Pan, Khaw, Seong Lin, Huang, David C.S., Ong, S. Tiong
Publicado 2015

A novel Bcr-Abl–mTOR–eIF4A axis regulates IRES-mediated translation of LEF-1

por Tsai, Becky Pinjou, Jimenez, Judith, Lim, Sharon, Fitzgerald, Kerry D., Zhang, Min, Chuah, Charles T. H., Axelrod, Haley, Nelson, Luke, Ong, S. Tiong, Semler, Bert L., Waterman, Marian L.
Publicado 2014

Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration

por Xiang, Wei, Cheong, Jit Kong, Ang, Shi Hui, Teo, Bryan, Xu, Peng, Asari, Kartini, Sun, Wen Tian, Than, Hein, Bunte, Ralph M., Virshup, David M., Chuah, Charles
Publicado 2015

The arginase inhibitor N(ω)−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as...

por Ng, King Pan, Manjeri, Aditi, Lee, Lin Ming, Chan, Zhu En, Tan, Chin Yee, Tan, Qiancheng Darren, Majeed, A'Qilah, Lee, Kian Leong, Chuah, Charles, Suda, Toshio, Ong, S. Tiong
Publicado 2018

Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia

por Zimdahl, Bryan, Ito, Takahiro, Blevins, Allen, Bajaj, Jeevisha, Konuma, Takaaki, Weeks, Joi, Koechlein, Claire S., Kwon, Hyog Young, Arami, Omead, Rizzieri, David, Broome, H. Elizabeth, Chuah, Charles, Oehler, Vivian G., Sasik, Roman, Hardiman, Gary, Reya, Tannishtha
Publicado 2014

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE:...

por Müller, Martin C., Cortes, Jorge, Chuah, Charles, Deangelo, Daniel, Deininger, Michael, Guilhot, François, Hughes, Timothy, Emmanuel Nicolini, Franck, Pinilla-Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Shah, Neil P., Talpaz, Moshe, Lu, Vickie, Padukkavidana, Thihan, Kantarjian, Hagop
Publicado 2023

P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB

por Cortes, Jorge, Deininger, Michael, Lomaia, Elza, Moiraghi, Beatriz, Undurraga, Soledad, Pavlovsky, Carolina, Chuah, Charles, Sacha, Tomasz, H. Lipton, Jeffrey, Mccloskey, James, Rousselot, Philippe, Rosti, Gianantonio, de Lavallade, Hugues, Rojas, Christine, Turkina, Anna, Talpaz, Moshe, Mauro, Michael, Lu, Vickie, Vorog, Alexander, Apperley, Jane
Publicado 2023

Regulation of myeloid leukemia by the cell fate determinant Musashi

por Ito, Takahiro, Kwon, Hyog Young, Zimdahl, Bryan, Congdon, Kendra L., Blum, Jordan, Lento, William E., Zhao, Chen, Lagoo, Anand, Gerrard, Gareth, Foroni, Letizia, Goldman, John, Goh, Harriet, Kim, Soo-Hyun, Kim, Dong-Wook, Chuah, Charles, Oehler, Vivian G., Radich, Jerald P., Jordan, Craig T., Reya, Tannishtha
Publicado 2010

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

por Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H.
Publicado 2018

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation

por Nicolini, Franck E., Basak, Grzegorz W., Kim, Dong‐Wook, Olavarria, Eduardo, Pinilla‐Ibarz, Javier, Apperley, Jane F., Hughes, Timothy, Niederwieser, Dietger, Mauro, Michael J., Chuah, Charles, Hochhaus, Andreas, Martinelli, Giovanni, DerSarkissian, Maral, Duh, Mei Sheng, McGarry, Lisa J., Kantarjian, Hagop M., Cortes, Jorge E.
Publicado 2017

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

por Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.
Publicado 2022

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

por Kantarjian, Hagop M., Jabbour, Elias, Deininger, Michael, Abruzzese, Elisabetta, Apperley, Jane, Cortes, Jorge, Chuah, Charles, DeAngelo, Daniel J., DiPersio, John, Hochhaus, Andreas, Lipton, Jeffrey, Nicolini, Franck E., Pinilla‐Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Srivastava, Shouryadeep, Ren, Xiaowei, Mauro, Michael
Publicado 2022